You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recombinant%20Human%20Hyaluronidase

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV Trial in Las Vegas (Cabotegravir 200 mg/mL, Cabotegravir 400 mg/mL, Recombinant human hyaluronidase PH20 (rHuPH20))

Recruiting
  • HIV Infections
  • Cabotegravir 200 mg/mL
  • +2 more
  • Orlando, Florida
  • +3 more
Dec 1, 2022

Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • TAK-881
  • HYQVIA
  • (no location specified)
Feb 23, 2023

Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC

Active, not recruiting
  • Multiple Myeloma
  • Daratumumab Subcutaneous (SC) Administration
  • Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
  • Atlanta, Georgia
  • +11 more
Aug 11, 2022

Healthy Trial in London (Ravulizumab, rHuPH20)

Completed
  • Healthy
  • London, United Kingdom
    Clinical Trial Site
May 25, 2022

HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)

Completed
  • HIV Antibodies
  • VRC-HIVMAB091-00-AB
  • EDP
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 8, 2022

Primary Immunodeficiency Diseases (PID) Trial (TAK-881)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • TAK-881
  • (no location specified)
Oct 4, 2023

Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8 Trial in Los Angeles (Atezolizumab

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +10 more
  • Atezolizumab and Recombinant Human Hyaluronidase
  • Survey Administration
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023

Healthy Volunteers Trial in Hialeah (TAK-881)

Completed
  • Healthy Volunteers
  • TAK-881
  • Hialeah, Florida
    Clinical Pharmacology of Miami
Apr 28, 2022

Outcomes Study (FIGARO)

Completed
  • Primary Immunodeficiency
  • Secondary Immune Deficiency
  • HyQvia
  • Paris, France
  • +3 more
Mar 18, 2022

Plasma Cell Myeloma Trial in Philadelphia (Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life

Not yet recruiting
  • Plasma Cell Myeloma
  • Daratumumab and Hyaluronidase-fihj
  • +3 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Aug 19, 2022

Primary Immunodeficiency Diseases (PID) Trial (TAK-771)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • (no location specified)
Aug 22, 2022

Hereditary Angioedema Trial in United States (CINRYZE with rHuPH20)

Completed
Has Results
  • Hereditary Angioedema
  • CINRYZE with rHuPH20
  • Scottsdale, Arizona
  • +3 more
Jun 16, 2021

Primary Immunodeficiency Diseases (PID) Trial in Centennial, North Palm Beach, Dallas (Recombinant human hyaluronidase + immune

Completed
  • Primary Immunodeficiency Diseases (PID)
  • Recombinant human hyaluronidase + immune globulin intravenous
  • Centennial, Colorado
  • +2 more
Apr 30, 2021

Bladder Cancer Trial in United States (Mitomycin C, Chemophase)

Completed
Has Results
  • Bladder Cancer
  • Phoenix, Arizona
  • +4 more
Sep 30, 2021

HIV Trial in Austin (VH3810109, rHuPH20)

Recruiting
  • HIV Infections
  • VH3810109
  • rHuPH20
  • Austin, Texas
    GSK Investigational Site
Sep 19, 2022

Primary Immunodeficiency Diseases (PID) Trial in Canada, United States (Recombinant human hyaluronidase (rHuPH20)+ immune

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
  • Cypress, California
  • +13 more
Apr 30, 2021

Plasma Cell Myeloma Trial (Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • (no location specified)
Dec 22, 2022

Hereditary Angioedema (HAE) Trial in Worldwide (CINRYZE with rHuPH20)

Completed
Has Results
  • Hereditary Angioedema (HAE)
  • CINRYZE with rHuPH20
  • Birmingham, Alabama
  • +22 more
May 11, 2021

Primary Immunodeficiency Diseases (PID) Trial in United States (Immune Globulin Infusion (Human), 10%, Recombinant human

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Immune Globulin Infusion (Human), 10%
  • Recombinant human hyaluronidase
  • Irvine, California
  • +9 more
Apr 30, 2021

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) Trial in Japan (TAK-771)

Recruiting
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Multifocal Motor Neuropathy (MMN)
  • Nagoya, Aichi, Japan
  • +16 more
Feb 2, 2023

HIV Trial in New Zealand, United States (Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL)

Recruiting
  • HIV Infections
  • Cabotegravir sodium (Oral Lead In)
  • +6 more
  • Orlando, Florida
  • +4 more
Mar 29, 2022

Tumors by Site Trial in Worldwide (nivolumab, rHuPH20)

Active, not recruiting
  • Neoplasms by Site
  • Atlanta, Georgia
  • +35 more
Jan 6, 2023

Metastatic Breast Cancer Trial in United States (Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase

Terminated
Has Results
  • Metastatic Breast Cancer
  • Eribulin mesylate
  • +2 more
  • Whittier, California
  • +6 more
Jun 25, 2020

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trial in Worldwide (HYQVIA)

Active, not recruiting
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • HYQVIA
  • Phoenix, Arizona
  • +34 more
Mar 21, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 30, 2021